{"database": "lobbying", "table": "lobbying_activities", "rows": [[3201383, "1886b452-4e1e-439a-93b8-18d5c5f4dceb", "Q2", "ERVIN GRAVES STRATEGY GROUP, LLC", 13836, "EMERGENT BIOSOLUTIONS INC.", 2024, "second_quarter", "DIS", "Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY24 and FY25; Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines; NDAA for Fiscal Year 2024 and Fiscal Year 2025 - provisions related to biological and chemical defense and access to naloxone; FAA reauthorization - increasing access to naloxone.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2024-07-18T17:55:23-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3201383"], "units": {}, "query_ms": 73.69131001178175, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}